Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
722.00    -2.00 (-0.28%)
Bid:
721.00
Ask:
769.00
Spread: 48.00 (6.657%)
Market Cap: £49.10m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Statement re possible acquisition

30 Dec 2015 07:00

RNS Number : 3726K
Silver Falcon PLC
30 December 2015
 

30 December 2015

SILVER FALCON PLC

("Silver Falcon" or the "Company")

 

Proposed acquisition of Lime Holdings Limited ("Lime")

 

Silver Falcon plc (LSE:SILF), the listed special purpose acquisition company, refers to its announcement of 23 December 2015 and is pleased to advise that it has entered into a non-binding Memorandum of Understanding with the board and principal shareholder in Lime Holdings Limited ("Lime") regarding a possible acquisition of 100% of the share capital of Lime by way of a share for share exchange ("Transaction").

Lime is an Australian unlisted public company which operates in the financial technology sector. It has developed an innovative platform for the insurance industry which facilitates the automated delivery of insurance to end users.

Lime has recently relocated its headquarters to the UK and is developing commercial partnerships in the UK and on an international basis.

Whilst a general understanding on the terms of the Transaction has been reached, these terms are subject to due diligence, a fundraising, and re-listing of the enlarged group on the London Stock Exchange. Accordingly there is no certainty that it will be completed.

If the Transaction is completed, it will constitute a reverse takeover under the Listing Rules. As the Company is unable to provide full disclosure under Rule 5.6.15 of the Listing Rules, the Company has requested a continuation of the current suspension of trading in its shares.

Further announcements will be made in due course as the Transaction progresses.

 

For further information please contact:

Silver Falcon: Tim Le Druillenec (Company Secretary), 07874 762821

Media enquiries: Jennifer Renwick, jennifer.renwick@camarco.co.uk, 0203 757 4994

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQTLBPTMBTTBAA
Date   Source Headline
9th May 20237:00 amRNSSubmission of IND for HEMO-CAR-T
28th Apr 202310:05 amRNSEquity Incentive Pool Increase and Option Grant
28th Apr 20237:00 amRNSFinal Results for the Year Ended 31 December 2022
23rd Mar 20231:32 pmRNSHEMO-CAR-T Analytical Release Tests Completed
28th Feb 20237:00 amRNSTotal Voting Rights
7th Feb 20232:30 pmRNSAdmission of Shares to Official List
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSPlacing to Raise £4,056,250
23rd Jan 20237:00 amRNSHEMO-CAR-T 3rd Process Qualification Run Completed
16th Jan 20234:40 pmRNSSecond Price Monitoring Extn
16th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
12th Jan 20234:40 pmRNSSecond Price Monitoring Extn
12th Jan 20234:35 pmRNSPrice Monitoring Extension
12th Jan 20232:05 pmRNSSecond Price Monitoring Extn
12th Jan 20232:00 pmRNSPrice Monitoring Extension
10th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20239:05 amRNSSecond Price Monitoring Extn
9th Jan 20239:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSSingle CBR Can Treat Multiple Viruses
5th Jan 20234:40 pmRNSSecond Price Monitoring Extn
5th Jan 20234:35 pmRNSPrice Monitoring Extension
5th Jan 202311:05 amRNSSecond Price Monitoring Extn
5th Jan 202311:00 amRNSPrice Monitoring Extension
4th Jan 20237:00 amRNSHEMO-CAR-T Process Qualification Run Completed
12th Dec 20227:00 amRNSHEMO-CAR-T First PQ Run Completed
18th Nov 20223:19 pmRNSHEMO-CAR-T Process Development Runs Completed
18th Nov 202211:05 amRNSSecond Price Monitoring Extn
18th Nov 202211:00 amRNSPrice Monitoring Extension
27th Oct 20224:40 pmRNSSecond Price Monitoring Extn
27th Oct 20224:35 pmRNSPrice Monitoring Extension
27th Oct 20222:05 pmRNSSecond Price Monitoring Extn
27th Oct 20222:00 pmRNSPrice Monitoring Extension
29th Sep 20228:00 amRNSHalf-year Report
1st Sep 20228:45 amRNSPresentation at H.C. Wainwright Global Conference
22nd Aug 20227:00 amRNSAppointment of Director of Quality
15th Aug 20227:00 amRNSApproval and Issuance of Antibody Patent
10th Aug 20227:00 amRNSAppointment of Medical Director
9th Aug 20222:06 pmRNSSecond Price Monitoring Extn
9th Aug 20222:00 pmRNSPrice Monitoring Extension
13th Jul 20227:00 amRNSNew Custom R&D Facility Opening
8th Jul 202212:25 pmRNSInvestor Webinar Recording
1st Jul 202212:19 pmRNSChange of Registered Office
30th Jun 20223:29 pmRNSResult of Annual General Meeting
27th Jun 20227:00 amRNSInvestor Webinar
7th Jun 20222:17 pmRNSPosting of Annual Report & Notice of AGM
30th May 20227:00 amRNSDirector/PDMR Shareholding
27th May 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.